Cisplatin functions primarily by cross-linking DNA, which results in apoptosis of rapidly dividing cancer cells; however, the drawback lies in its narrow therapeutic window. The toxicity to normal tissues, including nephrotoxicity and neurotoxicity, often limits the allowable dose. Furthermore, tumor resistance mechanisms, such as enhanced DNA repair and drug efflux, significantly reduce the chemotherapeutic impact. The current research seeks to address these challenges by integrating the natural bioactive compounds propolis and chrysin into a niosomal delivery system. Niosomes, vesicular carriers structurally similar to liposomes but composed of non-ionic surfactants, provide several advantages including enhanced stability, controlled release, and the ability to encapsulate both hydrophilic and hydrophobic substances.

Propolis, a resinous substance produced by bees, and chrysin, a plant-derived flavonoid, have each been recognized for their antitumor, anti-inflammatory, and antioxidant properties. The combined use of these two agents encapsulated within niosomes offers a dual mechanism to sensitize cancer cells to cisplatin, potentially overcoming drug resistance and reducing systemic toxicity. The nanoscale encapsulation also allows for targeted delivery, maximizing the concentration of the therapeutic agents at the tumor site while sparing healthy tissues.

The in vivo investigations conducted in murine cancer models demonstrated remarkable results. When administered alongside cisplatin, the niosomal formulations of propolis and chrysin significantly enhanced tumor regression compared to cisplatin alone. Notably, the treatment groups showed a marked reduction in tumor volume accompanied by improved survival rates. Histopathological analyses revealed decreased signs of cisplatin-induced organ damage, suggesting that these nanoadjuvants have a protective effect at the cellular level.

On a molecular scale, the synergistic activity seems to be mediated through modulation of key signaling pathways involved in apoptosis and oxidative stress. Both propolis and chrysin are known to induce the mitochondrial apoptotic pathway and downregulate anti-apoptotic proteins while combating the reactive oxygen species generated by cisplatin therapy. This action not only amplifies the cancer cell killing effect but also maintains redox homeostasis in normal cells, thereby reducing off-target toxicity.

From a pharmaceutical perspective, the formulation of propolis and chrysin into niosomes enhances their bioavailability, which is generally limited due to poor solubility and rapid metabolism. The nanosized carriers facilitate improved cellular uptake through enhanced permeability and retention (EPR) effect, a phenomenon that naturally drives nanoparticles to accumulate more in tumor tissues due to their leaky vasculature. As a result, these niosomal systems provide a robust platform for controlled and sustained drug release, ensuring effective concentrations over extended periods.

The authors also emphasize the importance of niosome surface properties in optimizing delivery. By adjusting the surfactant composition and cholesterol content, the niosomes exhibited high stability and an optimal size distribution for intravenous administration. These physicochemical properties are critical to evade rapid clearance by the mononuclear phagocyte system and to achieve prolonged circulation time, further enhancing the therapeutic outcome.

Crucially, the study addresses the complex interplay between cancer treatment efficacy and safety profiles, underscoring how nanotechnology-based drug delivery can revolutionize conventional chemotherapy. The utilization of natural compounds like propolis and chrysin highlights a shift toward integrating phytochemicals with established chemotherapeutics to forge synergistic regimens that are both more effective and bear fewer side effects.

Moreover, this research contributes to a growing body of evidence supporting the use of flavonoids and bee products as adjuncts in cancer therapy. Their immunomodulatory abilities, combined with antioxidant effects, not only potentiate chemotherapy but may also enhance the patient’s overall immune response against tumoral cells. This multi-pronged approach caters to the evolving understanding that successful cancer treatment necessitates attacking the disease on several biological fronts.

The findings herald potential clinical applications, with future directions including detailed pharmacokinetic and pharmacodynamic studies to translate this approach safely into human trials. Optimizing dosage regimens, scaling up niosomal production, and evaluating long-term toxicity profiles will be vital steps in advancing this promising nanomedicine from bench to bedside.

Furthermore, such nanoscale co-delivery systems can be adapted to other chemotherapeutic agents and phytochemicals, suggesting a versatile platform capable of customizing treatments according to tumor type and patient-specific factors. The precision and adaptability offered by nanotechnology could redefine personalized oncology and pave the way for more compassionate cancer care.

In summary, the innovative coupling of niosomal nanocarriers with natural adjuvants propolis and chrysin presents a compelling strategy to enhance cisplatin chemotherapy’s efficacy and safety. This synergistic drug delivery system leverages advancements in nanomedicine and natural product pharmacology to tackle longstanding challenges in chemotherapy, promising a brighter horizon for patients suffering from resistant cancers.

Subject of Research: Enhancing cisplatin chemotherapy efficacy and safety through the use of niosomal propolis and chrysin as nanoadjuvants in vivo.

Article Title: Improving cisplatin chemotherapy in vivo by niosomal propolis and chrysin as nanoadjuvants.

Article References:

Mohamad, E.A., El-Garhy, M.R. & Rageh, M.M. Improving cisplatin chemotherapy in vivo by niosomal propolis and chrysin as nanoadjuvants.
Med Oncol 42, 539 (2025). https://doi.org/10.1007/s12032-025-03105-5

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03105-5

The challenge of predicting how breast cancer will respond to chemotherapy remains a critical bottleneck in oncology. Traditional biopsy methods, though informative, offer limited insights and suffer from spatial sampling bias due to the heterogeneous nature of tumors. Radiomics, an emerging discipline that extracts high-dimensional quantitative features from medical images, offers an unprecedented window into tumor biology beyond what is visible to the naked eye. By integrating 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging with deep learning algorithms, the new approach captures complex tumor phenotypes and metabolic patterns associated with treatment efficacy.

At the heart of this research lies 18F-FDG PET/CT, a hybrid imaging modality that combines metabolic and anatomical information. 18F-FDG, a radiolabeled glucose analog, is preferentially taken up by highly metabolic tumor cells, enabling visualization of active malignancies and their aggressive phenotypes. The CT component, on the other hand, provides structural information that complements metabolic data. By employing deep radiomic modeling on this multi-dimensional dataset, the researchers developed algorithms capable of discerning subtle variations in tumor texture, intensity, and shape that correlate with chemotherapy responsiveness.

The study incorporated a robust dataset of breast cancer patients undergoing neoadjuvant chemotherapy, harnessing 18F-FDG PET/CT imaging data acquired at multiple time points. Through rigorous feature extraction and preprocessing, the team converted these images into comprehensive radiomic profiles. These profiles served as inputs for deep learning models—specifically convolutional neural networks—that were trained to identify patterns predictive of pathological complete response (pCR), a key indicator of effective chemotherapy. The models underwent stringent validation procedures to ensure generalizability and reliability.

Remarkably, the deep radiomic models demonstrated superior performance when compared to conventional clinical and imaging predictors. Metrics such as accuracy, sensitivity, and specificity in predicting chemotherapy outcomes were significantly enhanced, underscoring the efficacy of combining metabolic imaging with deep radiomics. Notably, the model’s ability to predict pCR prior to treatment initiation opens avenues for early therapeutic stratification, potentially sparing non-responders from unnecessary toxicity and guiding them toward alternative regimens.

One of the intrinsic advantages of this methodology is its non-invasive nature, relying solely on routinely acquired imaging to generate predictive insights. This feature not only reduces patient burden but also facilitates seamless integration into existing clinical workflows. Furthermore, the repeatability of PET/CT scans offers opportunities for dynamic monitoring, allowing clinicians to adjust treatment plans in response to early indications of therapy resistance or sensitivity.

The implications of this research extend beyond breast cancer. The paradigm of combining 18F-FDG PET/CT with deep radiomics could be extrapolated to other solid tumors where metabolic imaging is routinely performed, such as lung, head and neck, and gastrointestinal cancers. By unveiling intricate tumor heterogeneity and metabolic diversity, these models may serve as universal tools for personalized therapy evaluation and prognostication.

Despite the promising results, several challenges remain before widespread clinical deployment can be realized. Data standardization, including harmonization of imaging protocols and feature extraction methods, is essential to replicate results across institutions. Moreover, the interpretability of deep learning models—often criticized as “black boxes”—must be enhanced to provide clinicians with actionable insights and foster trust in automated decision-support systems. The development of hybrid models that integrate radiomics with genomic and molecular data might further bolster predictive power and elucidate underlying biological mechanisms.

Ethical considerations are also paramount as AI-driven diagnostics gain traction. Patient privacy, data security, and unbiased algorithmic design need careful stewardship to prevent disparities and ensure equitable healthcare delivery. Collaborative efforts among oncologists, radiologists, computer scientists, and ethicists will be central to navigating these complex issues.

Looking ahead, prospective clinical trials designed to evaluate the impact of radiomic-based predictions on treatment outcomes are crucial. Such studies will not only validate the clinical utility of these models but also help define standardized endpoints and regulatory pathways. Coupling radiomics with emerging imaging biomarkers, such as hypoxia or immune cell infiltration markers, could further refine response assessment, enabling a multi-dimensional view of tumor behavior.

The integration of artificial intelligence into oncological imaging heralds a new chapter wherein tailored therapies are informed by intricate data signatures invisible to traditional diagnostics. The study by Jiang and colleagues exemplifies how marrying metabolic PET/CT imaging with deep learning can transform chemotherapy response prediction in breast cancer, potentially improving survival rates and quality of life for countless patients.

In conclusion, 18F-FDG PET/CT-based deep radiomic models embody a promising convergence of technology and medicine, paving the way for a future in which cancer treatment is not just reactive but anticipatory and precisely calibrated to each patient’s unique tumor biology. As research in this domain accelerates, the prospect of realizing truly personalized oncology care becomes increasingly attainable, heralding transformative impacts on global cancer management.

Subject of Research:
Prediction of chemotherapy response in breast cancer using 18F-FDG PET/CT-based deep radiomic models.

Article Title:
18F-FDG PET/CT-based deep radiomic models for enhancing chemotherapy response prediction in breast cancer.

Article References:

Jiang, Z., Low, J., Huang, C. et al. 18F-FDG PET/CT-based deep radiomic models for enhancing chemotherapy response prediction in breast cancer.
Med Oncol 42, 425 (2025). https://doi.org/10.1007/s12032-025-02982-0

Image Credits: AI Generated